Renal Disease Treatments: Products and Therapies

The global market for renal disease treatments is an estimated $28 billion in 2009, but is expected to increase to $33.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 3.7%.

The largest segment of the market, chronic kidney disease (CKD) treatment products and therapies, is estimated to be nearly $27 billion in 2009, and is expected to increase at a CAGR of 3.6% through 2014 to reach nearly $32 billion.

The second-largest segment, acute renal failure (ARF) treatment products and therapies, is projected to grow at an 8.7% CAGR, from an estimated $955 million in 2009 to nearly $1.5 billion in 2014.

The smallest segment of the market, equipment, is projected to increase at a CAGR of 3.4%, from revenues of $276 million in 2009 to $326 million in 2014.

Renal failure can be either acute and temporary, or chronic and mostly irreversible. Either form may be due to a large number of other medical problems; long-term kidney problems have significant repercussions on other diseases. Once kidney failure is detected, the goal is preventing further deterioration of renal function.

The renal disease treatment market includes pharmaceutical products, renal replacement therapies, and surgical procedures. The choice of intervention largely depends on how far kidney failure has advanced and whether the condition is short term or permanent. Driving forces include an aging population, poor management of disease states, underlying kidney disease, and the increasing severity of illness of hospitalized patients.

This study aims to provide those interested in investment, acquisition, or expansion into the renal failure treatment market with specific, detailed information crucial to making informed decisions. Senior marketing personnel, venture capitalists, executive planners, and research directors should find the report of value.